New Strategies for the Prevention and Reduction of Cancer Treatment-Induced Diarrhea

Seminars in Oncology Nursing

Volumn 19, Issue SUPPL. 3, 2003, Pages 17-21

  Anthony, Lowell ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATROPINE PLUS DIPHENOXYLATE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; SOMATOSTATIN ANALOG; ANTIDIARRHEAL AGENT;

ANUS CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IRRADIATION; PELVIC GIRDLE; QUALITY OF LIFE; RADIATION DOSE; RECTUM CANCER; REVIEW; SIDE EFFECT; ALGORITHM; METHODOLOGY; NEOPLASM; NURSE PATIENT RELATIONSHIP; NURSING; ONCOLOGY NURSING; PATIENT EDUCATION; RADIATION INJURY; RISK FACTOR; STANDARD;

ALGORITHMS; ANTIDIARRHEALS; ANTINEOPLASTIC AGENTS; DIARRHEA; HUMANS; NEOPLASMS; NURSE-PATIENT RELATIONS; ONCOLOGIC NURSING; PATIENT EDUCATION; QUALITY OF LIFE; RADIATION INJURIES; RESEARCH DESIGN; RISK FACTORS;

EID: 85047694230     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.soncn.2003.09.010     Document Type: Article

References (11)

1. Wadler S, Benson AB III, Engelking G, et al: Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16:3169-3178, 1998
2. Ragnhammar P, Blomgren H: How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer. Med Oncol 12:187-201, 1995
3. Ragnhammar P, Hafstrom L, Nygren P, et al: A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40:282-308, 2001
4. Meropol NJ, Blumenson LE, Creaven PJ: Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. Am J Clin Oncol 21:135-138, 1998
5. Rubin J, Ajani J, Schirmer W, et al: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17:600-606, 1999
6. Rosenoff S: CID symptom resolution with long-acting octreotide depot. Proc Am Soc Clin Oncol 21:387a, 2002 (abstr 1545)
7. Rosenoff S: Octreotide LAR resolves severe chemotherapy-induced diarrhea (GID) and allows continuation of full-dose therapy. 2003 (abstr 3126). Available at: www.asco.org (accessed August 11, 2003)
8. Sandostatin LAR Depot (octreotide acetate for injectable suspension) prescribing information. East Hanover, NJ, Novartis Pharmaceuticals Corporation; September 2002
9. Anthony L, Ajani J: Sandostatin trial for the optimum prevention of CTID. Clinical study protocol. Novartis Pharmaceuticals Corporation, East Hanover, NJ
10. Martenson J: Double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy. Clinical study protocol. Novartis Pharmaceuticals Corporation, East Hanover, NJ
11. Zachariah B: The use of octreotide LAR depot to prevent or reduce the severity of chemoradiation-induced diarrhea in patients with anal or rectal cancer. Clinical study protocol. Novartis Pharmaceuticals Corporation, East Hanover, NJ